Prophylaxis for occupational exposure to HIV

Annals of Internal Medicine

Volumn 125, Issue 6, 1996, Pages 497-501

  Gerberding, Julie Louise ^a  

^a SAN FRANCISCO GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; DRUG DERIVATIVE; LAMIVUDINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; ZALCITABINE; ZIDOVUDINE;

HEALTH CARE PERSONNEL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; OCCUPATIONAL EXPOSURE; REVIEW;

ANTIVIRAL AGENTS; HEALTH PERSONNEL; HIV INFECTIONS; HUMANS; LAMIVUDINE; OCCUPATIONAL EXPOSURE; PROTEASE INHIBITORS; REVERSE TRANSCRIPTASE INHIBITORS; ZALCITABINE; ZIDOVUDINE;

EID: 0030587263     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-125-6-199609150-00011     Document Type: Article

References (19)

1. Gerberding JL. Management of occupational exposures to blood-borne viruses. N Engl J Med. 1996;332:444-51.
2. Ippolito G, Puro V, De Carli G. The risk of occupational human immunodeficiency virus infection in health care workers. Italian Multicenter Study. The Italian Study Group on Occupational Risk of HIV Infection. Arch Intern Med. 1993;153:1451-8.
3. Heptonstall J, Porter K, Gill ON. Occupational HIV: Summary of Published Reports. London: Public Health Laboratory Services Communicable Disease Surveillance Centre; 1995.
4. Case-control study of HIV seroconversion in health-care workers after percutaneous exposures to HIV-infected blood - France, United Kingdom, and United States, January 1988-August 1994. MMWR Morb Mortal Wkly Rep. 1995;44:929-33.
5. Saag MS, Grain MJ, Decker WD, Campbell-Hill S, Robinson S, Brown WE, et al. High-level viremia in adults and children infected with human immunodeficiency virus: relation to disease stage and CD4+ lymphocyte levels. J Infect Dis. 1991;164:72-80.
6. Ho DD, Moudgil T, Alam M. Quantitation of human immunodeficiency virus type 1 in the blood of infected persons. N Engl J Med. 1989; 321:1621-5.
7. Henderson DH, Gerberding JL. Prophylactic zidovudine after occupational exposure to the human immunodeficiency virus: an interim analysis. J Infect Dis. 1989;160:321-7.
8. Gerberding JL, Henderson DK. Management of occupational exposures to bloodborne pathogens: hepatitis B virus, hepatitis C virus, and human immunodeficiency virus. Clin Infect Dis. 1992;14:1179-85.
9. Clerici M, Levin JM, Kessler HA, Harris A, Berzofsky JA, Landay AL, et al. HIV-specific T-helper activity in seronegative health care workers exposed to contaminated blood. JAMA. 1994;271:42-6.
10. Tavares L, Roneker C, Johnston K, Lehrman SN, de Noronha F. 3′-azido-3′deoxythymidine in feline leukemic virus-infected cats: a model for therapy and prophylaxis of AIDS. Cancer Res. 1987; 47:3190-4.
11. Mathes LE, Polas PJ, Hayes KA, Swenson CL, Johnson S, Kociba GJ. Pre- and postexposure chemoprophylaxis: evidence that 3′-azido-3′-dideoxythymidine inhibits feline leukemia virus disease by a drug-induced vaccine response. Antimicrob Agents Chemother. 1992; 36:2715-21.
12. Ruprecht RM, O'Brien LG, Rossoni LD, Nusinoff-Lehrman S. Suppression of mouse viraemia and retroviral disease by 3′-azido-3′-deoxythymidine. Nature. 1986;323:467-9.
13. McCune JM, Namikawa R, Shih CC, Rabin L, Kaneshima H. Suppression of HIV infection in AZT-treated SCID-hu mice. Science. 1990;247:564-6.
14. Van Rompay KK, Marthas ML, Ramos RA, Mandell CP, McGowan EK, Joye SM, et al. Simian immunodeficiency virus (SIV) infection of infant rhesus macaques as a model to test antiretroviral drug prophylaxis and therapy: oral 3′-azido-3′-deoxythymidine prevents SIV infection. Antimicrob Agents Chemother. 1992;36:2381-6.
15. LaFon SW, Lehrman SN, Barry DW. Prophylactically administered Retrovir in health care workers potentially exposed to the human immunodeficiency virus. J Infect Dis. 1988;158:503.
16. LaFon SW, Mooney BD, McMullen JP, Pattishall KH, Smiley ML, Roques MO, et al. A double-blind, placebo-controlled study of the safety and efficacy of Retrovir (zidovudine, ZDV) as a chemoprophylactic agent in health care workers [Abstract]. In: Program and Abstracts - Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology; 1990:489.
17. Connor EM, Sperling RS, Gelber R, Kiselev P, Scott G, O'Sullivan MJ, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med. 1994;331:1173-80.
18. Fahrner R, Beekmann SE, Koziol DE, Gerberding JL, Henderson DK. Safety of zidovudine (ZDV) administered as post-exposure prophylaxis to health care workers (HCW) sustaining HIV-related occupational exposures (OE) [Abstract]. In: Program and Abstracts - Intersdence Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology; 1994:133.
19. Puro V, Ippolito G, Guzzanti E, Serafin I, Pagano G, Suter F, et al. Zidovudine prophylaxis after accidental exposure to HIV: the Italian experience. The Italian Study Group on Occupational Risk of HIV Infection. AIDS. 1992;6:963-9.